Quantys is a Contract Research Organization (CRO), established to provide world class services in bioequivalence testing to the pharmaceutical and nutraceutical industries.
Established in April 2016, Quantys is located in Kandla SEZ (KASEZ), Gujarat (India). The facility is spread over 40,000 sq. ft. with operations such as Clinical, Bio analytical, Pharmacokinetic & Statistical, Medical Writing, QA & RA, and Quantys to offer. With full time doctors and paramedical staff, Quantys consists of 104 beds segregated into 5 independent clinics, with a large volunteer database and a state of the art bio-analytical laboratory consisting of 4 LC-MS/MS.
The high-quality clinical trial services offered, brings forward an end-to- end capability across both the clinical development and regulatory affairs to drive the desired outcomes.
With the increasing demand of generic R&D organizations and a race towards first-to- market advantage and an increasing regulatory pressure on prices, the BA/BE market plays an essential role in the ‘Life Science’ sector. To bring a generic drug to market, pharmaceutical companies need to compete with many key aspects:
- Firstly, to market a product it is essential to be the first company awarded 6 months exclusivity to gain market footprint.
- Secondly, accurate bioanalytical capability is essential to determine bioequivalence.
- Thirdly, regulatory requirements of study quality remain as high as innovator.
Our Mission
To achieve a leading presence with local expertise in an expanding geography of international CRO markets, through a network of selected partners, and providing cutting edge infrastructure.
Our Vision
To provide contracted clinical research services with ensured compliance, in targeted international and domestic markets, through a team of committed experts and we strive to be long-term trusted partners of major health organisations and pharmaceutical Companies.
LEADERSHIP TEAM
Dr. Kunal Saxena - Managing Director, Quantys Clinical Pvt. Ltd.
He has done his PhD in Pharmacology from the University of Bristol (UK), M.Sc. in Chemistry from Moscow State University (Moscow, Russia) and B.Sc. in Biochemistry from University of Notre Dame (USA). He has done basic research in the area of opioid receptor and developed several novel non-opioid compounds which help reduce side effects and tolerance to opioid analgesics.
His work on basic opioid receptor pharmacology has been published in some of the leading journals such as Journal of Molecular Pharmacology, Journal of Neurochemistry, journal of Biological Chemistry.